Chronic Myeloid Leukemia
Test launched to monitor Gleevec resistance
Published in Blood Weekly, March 9th, 2006
Despite high response rates to Gleevec, approximately 4-5% of patients who were initially treated successfully will develop resistance during therapy. Genzyme's new BCR-ABL Mutation Analysis test will assist physicians in evaluating resistance to therapy and facilitate appropriate adjustments to treatment.
The molecular hallmark of CML is a mutation known as BCR-ABL. This mutation is the specific target for Gleevec and is found in 95% of patients with CML. In relapse...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-03-09)
More Articles from Blood Weekly
- Blood Banking
Optimized method filters buffy coats as a replacement for standard buffy coats - Blood Banking
Sample errors account for majority of near-miss events in blood transfusions - Cardiac Allograft
Lymphoid sequestration of alloreactive CD4 cells promotes cardiac allograft survival - Stem Cell Transplantation
HLA-DPB1 matching status in HSCT associated with increased risk of disease relapse - Stem Cell Transplantation
p18(INK4C) deletion results in improved long-term HSC engraftment - Alcoholic Hepatitis
ADAMTS13 may contribute to multiorgan failure in alcoholic hepatitis - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
